Stay updated on NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    - Revision: v3.3.4 updated from v3.3.3.
    Difference
    0.0%
    Check dated 2026-01-13T17:45:11.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Locations now list multiple states (Arizona, California, Florida, Georgia, Kansas, Michigan, Minnesota, New York, North Carolina, Ohio, Oregon, Texas, Washington), expanding trial site access. Revision: v3.3.3 appears after v3.3.2.
    Difference
    1%
    Check dated 2025-12-23T08:28:54.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    A new revision tag 'Revision: v3.3.2' is shown and the prior 'Revision: v3.3.1' tag is removed. This is a minor administrative update that does not change study information or user-facing functionality.
    Difference
    0.0%
    Check dated 2025-12-01T17:11:18.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The Publications section now states that these publications are automatically filled in from PubMed and shows Revision: v3.3.1, replacing the prior note tied to v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T14:35:51.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The general government funding/operating status notice was removed from the page. Study details and links remain unchanged.
    Difference
    0.3%
    Check dated 2025-11-17T06:53:34.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    The REVEAL trial was terminated after Phase 1 results, and Phase 2 will not proceed. The termination was not due to safety concerns.
    Difference
    0.4%
    Check dated 2025-11-03T01:20:27.000Z thumbnail image

Stay in the know with updates to NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.